Cargando…

Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report

BACKGROUND: Ifosfamide is an alkylating agent used in the treatment of a wide range of tumours. Because of known side effects it is usually administered in combination with mesna, a thiol agent with uroprotective activity, to reduce them and increase the therapeutic dose. The most frequently adminis...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado-Prada, Ana, Borrás, Julián, Farzanegan, Roxana, Torres Gorriz, María Cruz, Germán-Sánchez, Adrián, Cervera Aznar, Raquel, Raducan, Isabela, Castelló, Jose Vicente, Sanchez-Hernandez, Alfredo, Enrique, Ernesto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125806/
https://www.ncbi.nlm.nih.gov/pubmed/35606850
http://dx.doi.org/10.1186/s12948-022-00173-0
_version_ 1784712009469657088
author Delgado-Prada, Ana
Borrás, Julián
Farzanegan, Roxana
Torres Gorriz, María Cruz
Germán-Sánchez, Adrián
Cervera Aznar, Raquel
Raducan, Isabela
Castelló, Jose Vicente
Sanchez-Hernandez, Alfredo
Enrique, Ernesto
author_facet Delgado-Prada, Ana
Borrás, Julián
Farzanegan, Roxana
Torres Gorriz, María Cruz
Germán-Sánchez, Adrián
Cervera Aznar, Raquel
Raducan, Isabela
Castelló, Jose Vicente
Sanchez-Hernandez, Alfredo
Enrique, Ernesto
author_sort Delgado-Prada, Ana
collection PubMed
description BACKGROUND: Ifosfamide is an alkylating agent used in the treatment of a wide range of tumours. Because of known side effects it is usually administered in combination with mesna, a thiol agent with uroprotective activity, to reduce them and increase the therapeutic dose. The most frequently administered regimens for ifosfamide are fractionated doses for 3 to 5 days, high-dose intravenous bolus, and continuous infusion over 24 to 72 h. Hypersensitivity reactions to ifosfamide plus mesna are not frequently described in the literature. Moreover, no reports exist concerning desensitization for this chemotherapy combination. CASE PRESENTATION: A 47-year-old man with stage IV renal sarcoma was treated with the combination of ifosfamide and mesna every 3 weeks in a 4-consecutive-day infusion protocol. During the second cycle of chemotherapy, he presented acute cutaneous symptoms. A 12-step desensitization protocol was proposed in view of the lack of knowledge of the possible hypersensitivity reactions to this combination of chemotherapy agents, and the multiple difficulties found during the study of the case. CONCLUSIONS: The 12-step desensitization protocol was well tolerated. Therefore, it is an appropriate and safe option in the case of suspected allergy to ifosfamide plus mesna.
format Online
Article
Text
id pubmed-9125806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91258062022-05-24 Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report Delgado-Prada, Ana Borrás, Julián Farzanegan, Roxana Torres Gorriz, María Cruz Germán-Sánchez, Adrián Cervera Aznar, Raquel Raducan, Isabela Castelló, Jose Vicente Sanchez-Hernandez, Alfredo Enrique, Ernesto Clin Mol Allergy Case Report BACKGROUND: Ifosfamide is an alkylating agent used in the treatment of a wide range of tumours. Because of known side effects it is usually administered in combination with mesna, a thiol agent with uroprotective activity, to reduce them and increase the therapeutic dose. The most frequently administered regimens for ifosfamide are fractionated doses for 3 to 5 days, high-dose intravenous bolus, and continuous infusion over 24 to 72 h. Hypersensitivity reactions to ifosfamide plus mesna are not frequently described in the literature. Moreover, no reports exist concerning desensitization for this chemotherapy combination. CASE PRESENTATION: A 47-year-old man with stage IV renal sarcoma was treated with the combination of ifosfamide and mesna every 3 weeks in a 4-consecutive-day infusion protocol. During the second cycle of chemotherapy, he presented acute cutaneous symptoms. A 12-step desensitization protocol was proposed in view of the lack of knowledge of the possible hypersensitivity reactions to this combination of chemotherapy agents, and the multiple difficulties found during the study of the case. CONCLUSIONS: The 12-step desensitization protocol was well tolerated. Therefore, it is an appropriate and safe option in the case of suspected allergy to ifosfamide plus mesna. BioMed Central 2022-05-23 /pmc/articles/PMC9125806/ /pubmed/35606850 http://dx.doi.org/10.1186/s12948-022-00173-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Delgado-Prada, Ana
Borrás, Julián
Farzanegan, Roxana
Torres Gorriz, María Cruz
Germán-Sánchez, Adrián
Cervera Aznar, Raquel
Raducan, Isabela
Castelló, Jose Vicente
Sanchez-Hernandez, Alfredo
Enrique, Ernesto
Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report
title Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report
title_full Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report
title_fullStr Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report
title_full_unstemmed Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report
title_short Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report
title_sort cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125806/
https://www.ncbi.nlm.nih.gov/pubmed/35606850
http://dx.doi.org/10.1186/s12948-022-00173-0
work_keys_str_mv AT delgadopradaana cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport
AT borrasjulian cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport
AT farzaneganroxana cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport
AT torresgorrizmariacruz cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport
AT germansanchezadrian cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport
AT cerveraaznarraquel cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport
AT raducanisabela cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport
AT castellojosevicente cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport
AT sanchezhernandezalfredo cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport
AT enriqueernesto cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport